Werewolf Therapeutics Inc (HOWL) Stock Price, Quote & News

Company Profile

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activa...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 952 0555

Website: werewolftx.com

Address:

200 Talcott Ave, 2nd Floor, Watertown, United States

Vikingsstrade Oct. 3 at 5:04 PM

Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve! $ICE $SEI $HOWL $GEVO

0 · Reply

johnjaha Oct. 3 at 4:23 PM

$HOWL

0 · Reply

elmono Oct. 2 at 2:44 PM

$HOWL soon

0 · Reply

LabPsycho Oct. 2 at 2:39 PM

$HOWL Although HOWL may have recovered back up to ~ $2 from that flash crash recently down to ~ $1.77, in my observations, when a biotech stock does this, it usually retraces below that previous spike low. Even @ $1.65, there are still a lot of shares the past 6 months with decent % gains. Good luck

0 · Reply

ALOSETE Oct. 1 at 3:08 PM

$HOWL buying here.

0 · Reply

David_M_ Oct. 1 at 2:32 PM

$HOWL I don't care. My DD is that the ticker is Howl and it's called Werewolf. I'm long on this one.

1 · Reply

aerts2js Sep. 30 at 6:51 PM

$HOWL all of their stuff is still in phase one.. this isn’t even close to coming to fruition.

0 · Reply

_www_larval_com_ Sep. 30 at 3:17 PM

$HOWL has sunk -18% lower to -23% (~668Kv) moments ago, 10/17 options, follow for more volatility.

0 · Reply

Wazaby44 Sep. 30 at 3:17 PM

$HOWL what is going on ?

1 · Reply

David_M_ Sep. 30 at 1:00 PM

$HOWL

0 · Reply

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

Sep 2, 2025, 8:00 AM EDT - 4 weeks ago

Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference

Aug 14, 2025, 7:00 AM EDT - 7 weeks ago

Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 9, 2025, 8:00 AM EDT - 3 months ago

Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit

Jun 12, 2025, 8:00 AM EDT - 4 months ago

Werewolf Therapeutics to Participate in the BIO International Convention

May 29, 2025, 8:00 AM EDT - 4 months ago

Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference

May 20, 2025, 4:01 PM EDT - 4 months ago

HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124

May 13, 2025, 8:00 AM EDT - 5 months ago

Werewolf Therapeutics to Participate in Hanson Wade's 6th Annual Cytokine-Based Drug Development Summit

May 8, 2025, 7:00 AM EDT - 5 months ago

Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 5, 2025, 8:05 AM EDT - 5 months ago

Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

May 5, 2025, 8:00 AM EDT - 5 months ago

Werewolf Therapeutics to Participate in Upcoming Investor Conferences

Apr 17, 2025, 8:00 AM EDT - 6 months ago

Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer

Mar 31, 2025, 8:00 AM EDT - 6 months ago

Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 11, 2025, 7:00 AM EDT - 7 months ago

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 4, 2025, 8:00 AM EST - 7 months ago

Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference

Feb 24, 2025, 7:30 AM EST - 7 months ago

Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors

Jan 13, 2025, 8:00 AM EST - 9 months ago

Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook

Nov 20, 2024, 8:00 AM EST - 11 months ago

Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference

Nov 7, 2024, 9:02 AM EST - 11 months ago

Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Oct 4, 2024, 9:00 AM EDT - 1 year ago

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Aug 8, 2024, 7:05 AM EDT - 1 year ago

Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 1, 2024, 10:04 AM EDT - 1 year ago

Werewolf Therapeutics: Continuing To Advance And Show More Promise In Phase 1

Jun 25, 2024, 7:00 AM EDT - 1 year ago

Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma

Jun 1, 2024, 9:00 AM EDT - 1 year ago

Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors

May 30, 2024, 8:00 AM EDT - 1 year ago

Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference

May 23, 2024, 5:00 PM EDT - 1 year ago

Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting

May 3, 2024, 7:00 AM EDT - 1 year ago

Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 24, 2024, 10:05 AM EDT - 1 year ago

Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 23, 2024, 8:00 AM EDT - 1 year ago

Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

Apr 5, 2024, 4:30 PM EDT - 1 year ago

Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting

Apr 4, 2024, 4:57 PM EDT - 1 year ago

Werewolf Therapeutics: In The Hunt For Success In The Cytokine Space

Apr 4, 2024, 4:30 PM EDT - 1 year ago

Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting

Mar 7, 2024, 7:00 AM EST - 1 year ago

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 6, 2024, 8:00 AM EST - 1 year ago

Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference

Mar 5, 2024, 4:30 PM EST - 1 year ago

Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024

Jan 8, 2024, 7:00 AM EST - 1 year ago

Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook

Jan 4, 2024, 4:05 PM EST - 1 year ago

Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors

Dec 28, 2023, 7:09 PM EST - 1 year ago

Werewolf Therapeutics: Still In The Race To Develop Next Generation Cytokines

Nov 22, 2023, 7:00 AM EST - 2 years ago

Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference

Nov 14, 2023, 4:25 PM EST - 2 years ago

Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 6, 2023, 5:14 PM EST - 2 years ago

Werewolf Therapeutics: Possibly A Transformative IL-2, But Still Early Days

Nov 3, 2023, 7:00 AM EDT - 2 years ago

Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Oct 31, 2023, 9:00 AM EDT - 2 years ago

Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Sep 27, 2023, 9:00 AM EDT - 2 years ago

Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Sep 11, 2023, 4:05 PM EDT - 2 years ago

Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124

Aug 25, 2023, 4:48 PM EDT - 2 years ago

Werewolf: Q4 2023 Data Readout And Enhancement Of Validated Targets

Aug 10, 2023, 7:10 AM EDT - 2 years ago

Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Jun 1, 2023, 7:00 AM EDT - 2 years ago

Werewolf Therapeutics to Present at the Jefferies Healthcare Conference

May 11, 2023, 7:00 AM EDT - 2 years ago

Werewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 1, 2023, 7:00 AM EDT - 2 years ago

Werewolf Therapeutics to Participate in May Investor Conferences

Vikingsstrade Oct. 3 at 5:04 PM

0 · Reply

johnjaha Oct. 3 at 4:23 PM

$HOWL

0 · Reply

elmono Oct. 2 at 2:44 PM

$HOWL soon

0 · Reply

LabPsycho Oct. 2 at 2:39 PM

0 · Reply

ALOSETE Oct. 1 at 3:08 PM

$HOWL buying here.

0 · Reply

David_M_ Oct. 1 at 2:32 PM

$HOWL I don't care. My DD is that the ticker is Howl and it's called Werewolf. I'm long on this one.

1 · Reply

aerts2js Sep. 30 at 6:51 PM

$HOWL all of their stuff is still in phase one.. this isn’t even close to coming to fruition.

0 · Reply

_www_larval_com_ Sep. 30 at 3:17 PM

$HOWL has sunk -18% lower to -23% (~668Kv) moments ago, 10/17 options, follow for more volatility.

0 · Reply

Wazaby44 Sep. 30 at 3:17 PM

$HOWL what is going on ?

1 · Reply

David_M_ Sep. 30 at 1:00 PM

$HOWL

0 · Reply

highnihilism Sep. 30 at 10:37 AM

$RLMD Relmada Therapeutics: 136 trades, $28K vs $6K avg (4.38x !!). $28K calls / $0 puts. $MDWD Mediwound: 9 trades, $28K vs $14K avg (1.98x). $28K calls / $0.4K puts. $NRP Natural Resources: 24 trades, $29K vs $26K avg (1.10x). $27K calls / $1K puts. $HOWL Werewolf Therapeutics: 63 trades, $30K vs $5K avg (6.04x !!). $27K calls / $3K puts.

0 · Reply

johnjaha Sep. 30 at 3:03 AM

$HOWL Only question is it 5x or 10x?

0 · Reply

StockScanners Sep. 30 at 1:16 AM

$HOWL reached 2.38

1 · Reply

aerts2js Sep. 29 at 9:03 PM

$HOWL thinking about jumping in, but I hate chasing the run upward with penny stocks.. what news warranted the recent 50% increase?

2 · Reply

sumedocin4 Sep. 29 at 8:31 PM

$HOWL Howlin for Werewolf!

0 · Reply

CoachHendo Sep. 29 at 5:16 PM

$HOWL 💥 💥 BOOM

0 · Reply

_www_larval_com_ Sep. 29 at 3:48 PM

$HOWL has shot 3% higher to 11% (~1Mv) in the last few minutes, 10/17 options, follow for more volatility.

0 · Reply

LNoughtMM Sep. 29 at 2:50 PM

$HOWL

0 · Reply

johnjaha Sep. 29 at 1:58 PM

$HOWL I like this chart. $5+

0 · Reply

Wazaby44 Sep. 29 at 8:21 AM

$HOWL - Early monotherapy data already promising, with combo expansion readout in Q4. Ultra-low market cap in immuno-oncology means huge upside leverage. Recent break of the bullish curve - above all SMAs - don't miss the train $$:

0 · Reply

StockScanners Sep. 27 at 6:32 AM

$HOWL reached 2.29

0 · Reply

David_M_ Sep. 27 at 1:57 AM

$HOWL Why with a name like Werewolf a ticker like HOWL and this in an uptrend does this page have so few followers?

3 · Reply

Market Cap	93.74M
Revenue (ttm)	1.89M
Net Income (ttm)	-70.52M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3,731.22%
Debt to Equity Ratio	0.60

Volume	1,037,000
Avg Vol	472,572
Day's Range	N/A - N/A
Shares Out	45.73M
Stochastic %K	57%
Beta	0.76
Analysts	Strong Sell
Price Target	$6.83